ArchPoint Investors’s GSK GSK Stock Holding History

ArchPoint Investors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-12,744	Closed	-$652K	–	154
2017 Q3	$652K	Buy	12,744 +2,472	+24%	+$125K	0.21%	60
2017 Q2	$559K	Hold	10,272	–	–	0.18%	64
2017 Q1	$547K	Sell	10,272 -2,064	-17%	-$105K	0.21%	51
2016 Q4	$594K	Buy	12,336 +4,464	+57%	+$221K	0.35%	46
2016 Q3	$424K	Hold	7,872	–	–	0.24%	51
2016 Q2	$426K	Sell	7,872 -1,156	-13%	-$60.9K	0.24%	52
2016 Q1	$458K	Hold	9,028	–	–	0.25%	45
2015 Q4	$455K	Buy	9,028 +280	+3%	+$14.3K	0.32%	49
2015 Q3	$420K	Buy	8,748 +200	+2%	+$10.4K	0.29%	54
2015 Q2	$445K	Sell	8,548 -16	-0.2%	-$901	0.28%	57
2015 Q1	$494K	Hold	8,564	–	–	0.34%	48
2014 Q4	$458K	Buy	8,564 +1,476	+21%	+$82.6K	0.34%	63
2014 Q3	$407K	Buy	7,088 +1,224	+21%	+$75K	0.34%	50
2014 Q2	$392K	Buy	5,864 +672	+13%	+$45.5K	0.33%	51
2014 Q1	$347K	Hold	5,192	–	–	0.31%	55
2013 Q4	$347K	Buy	5,192 +40	+0.8%	+$2.59K	0.32%	52
2013 Q3	$323K	Hold	5,152	–	–	0.36%	52
2013 Q2	$322K	Buy	+5,152	New	+$327K	0.38%	51

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ArchPoint Investors's GSK Position: Q4 2017 in Review

ArchPoint Investors sold out of GSK (GSK) in Q4 2017, closing a stake of 12,744 shares — an estimated $652K sold.

ArchPoint Investors first reported a position in GSK in Q2 2013 and held it in 18 quarters. The position peaked at $652K in Q3 2017. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

ArchPoint Investors reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
ArchPoint Investors sold 12,744 GSK shares in Q4 2017, an estimated $652K.
ArchPoint Investors first reported a position in GSK in Q2 2013 and held it in 18 quarters.
ArchPoint Investors's GSK position peaked at $652K in Q3 2017.
763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on ArchPoint Investors's 13F filing for Q4 2017, filed 14 Feb 2018.